Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909284 | 0.86 | CYP2C19 (0.53) | CYP2C19EPHX1CYP2D6SRCCNR1 | |
| SCHEMBL11637533 | 0.86 | CYP2C19 (0.44) | CYP2C19EPHX1CYP2D6SRCCNR1 | |
| SCHEMBL7830236 | 0.86 | CYP2C19 (0.53) | CYP2C19EPHX1CYP2D6SRCCNR1 | |
| Hydrochloric Acid SCHEMBL908468 | 0.84 | CYP2C19 (0.52) | CYP2C19EPHX1CYP2D6SRCLMNA | |
| SCHEMBL7255213 | 0.83 | CYP2C19 (0.46) | CYP2C19EPHX1CYP2D6SRCLMNA | |
| SCHEMBL9066698 | 0.82 | CYP2C19 (0.42) | CYP2C19EPHX1CYP2D6SRCCNR1 | |
| SCHEMBL28223379 | 0.82 | EPHX1 (0.59) | CYP2C19EPHX1CYP2D6SRCCNR1 | |
| SCHEMBL971454 | 0.82 | CYP2C19 (0.48) | CYP2C19EPHX1CYP2D6LMNAHSD17B10 | |
| SCHEMBL13658246 | 0.81 | POLB (0.50) | CYP2C19EPHX1LMNAHSD17B10KCNQ2 | |
| SCHEMBL19612626 | 0.79 | POLB (0.50) | CNR2LMNAHSD17B10KCNQ2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| CN-101815713-B | Polycyclic compounds | EISAI R&D MAN CO LTD | 2013-09-11 | — | — | CN | disclosed |
| EP-2181992-B1 | POLYCYCLIC COMPOUND | EISAI R&D MAN CO LTD (JP) | 2013-05-01 | — | — | EP | disclosed |
| EP-2559693-A1 | Polycyclic compound | Eisai R&D Management Co., Ltd. (JP) | 2013-02-20 | — | — | EP | disclosed |
| US-7935815-B2 | Imidazoyl pyridine compounds and salts thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | KIMURA TEIJI | 2011-03-17 | — | — | US | disclosed |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-7816360-B2 | Microsomal triglyceride transfer protein (MTP) inhibitors, used for the treatment of atherosclerosis, pancreatitis, obesity, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and non-insulin dependent diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| CN-101815713-A | Polycyclic compounds | EISAI R&D MAN CO LTD | 2010-08-25 | — | — | CN | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20100004263-A1 | MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES | MEERPOEL LIEVEN | 2010-01-07 | — | — | US | disclosed |
| US-7504400-B2 | for the treatment of atherosclerosis, pancreatitis, obesity, hyper-triglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes; apolipoprotein B secretion inhibitors also for lipid lowering activity; compounds can selectively block MTP at the level of the gut wall in mammals | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-17 | — | — | US | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1751131-B1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-19 | — | — | EP | disclosed |
| US-20070191383-A1 | Mtp inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| CN-1930143-A | MTP inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles | JANSSEN PHARMACEUTICA NV (BE) | 2007-03-14 | — | — | CN | disclosed |
| EP-1751131-A1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005085226-A1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009619-A1 | POLYCYCLIC COMPOUND | APP, BACE1, PSEN1 | CYP2C19 2240/4885EPHX1 204/4885CYP2D6 1746/4885 |
| US-20070191383-A1 | Mtp inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles | APOB, PNLIP, LPL | CYP2C19 2390/4885EPHX1 1824/4885CYP2D6 3245/4885 |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | APP, PSEN1, BACE1 | CYP2C19 2394/4885EPHX1 199/4885CYP2D6 793/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | CYP2C19 2903/4885EPHX1 90/4885CYP2D6 1874/4885 |
| US-20100004263-A1 | MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES | PNLIP, LPL, APOB | CYP2C19 2494/4885EPHX1 1441/4885CYP2D6 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.